ong-term administration study of E3810 for the prevention of gastric or duodenal ulcer caused by low-dose aspiri
Phase 2
- Conditions
- Gastric or duodenal ulcers caused by low-dose aspirin
- Registration Number
- JPRN-jRCT2080221500
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Confirmed to have no recurrence of gastric or duodenal ulcer by endoscopy at the end of 24 weeks of treatment in Trial 308.
Need to continue receiving low-dose aspirin (81 mg/day or 100 mg/day) during this trial.
Exclusion Criteria
Confirmed to have a recurrence of gastric or duodenal ulcer at the end of 24 weeks of treatment in Trial 308 (at the start of this trial) and thus are withdrawn from the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method